Early Assessment of Circulating Tumor Cells and Their PD-L1 Expression as Predictive Biomarkers in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy: An Exploratory Study
Blood tests measuring tumor cell counts and PD-L1 levels offer real-time monitoring of treatment response in lung cancer without invasive biopsies.
This prospective study evaluated early circulating tumor cell counts and PD-L1 expression as prognostic biomarkers in metastatic NSCLC patients undergoing systemic therapy. CTC PD-L1 assessment offers a minimally invasive strategy for real-time treatment monitoring in NSCLC, where therapeutic benefit remains heterogeneous.
What the study was
- Study design
- Prospective cohort study
- Population
- Metastatic NSCLC patients receiving systemic therapy
- Category
- Early Detection
- Maturity
- Validated
- Journal
- ImmunoTargets and therapy
Why it surfaced
Prospective evaluation of CTC PD-L1 as liquid biopsy biomarker in NSCLC; relevant to both early detection surveillance and immunotherapy monitoring.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.